Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success.
LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries. The tool is meant only for patients with a severe form of peripheral artery disease, and who have already tried more conservative options.
Dan Rose, CEO of LimFlow, previously told STAT that his mission is to fight the amputation epidemic in the United States, which disproportionately impacts Black patients. Experts cautioned to STAT that expanding screenings to catch the disease early is still the most important measure.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect